<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666406</url>
  </required_header>
  <id_info>
    <org_study_id>060601</org_study_id>
    <nct_id>NCT00666406</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A</brief_title>
  <official_title>Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A: a Phase IV, Prospective, Randomized, Controlled, Cross-over, Single Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetic parameters and safety of Advate
      rAHF-PFM versus Recombinate rAHF in well described previously treated patients with severe
      hemophilia A (factor VIII level &lt; 1%).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. One-Stage Activated Partial Thromboplastin Time (aPTT) -Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.
FVIII activity measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (Cl). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (C-max). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (C-max). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (C-max). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (C-max). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations (9 to 48 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Increase in factor VIII concentration from pre- to post-infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the terminal or disposition rate constant obtained from log_e -linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Increase in factor VIII concentration from pre- to post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Increase in factor VIII concentration from pre- to post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted Clearance * Mean Residence Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted Clearance (CL) * Mean Residence Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted CL * Mean Residence Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</measure>
    <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted CL * Mean Residence Time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advate rAHF-PFM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinate rAHF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)</intervention_name>
    <description>Infusion of 50 +/- 5 IU/kg bodyweight</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Advate rAHF-PFM</other_name>
    <other_name>Recombinant Protein-Free Factor VIII (rAHF-PFM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Factor VIII (rAHF)</intervention_name>
    <description>Infusion of 50 +/- 5 IU/kg bodyweight</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Recombinate rAHF</other_name>
    <other_name>Antihemophilic Factor (Recombinant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent obtained from participant or legally authorized representative

          -  15-60 years old

          -  Factor VIII level &lt; 1% as documented by previously measured factor VIII and genotyping

          -  Previously treated with factor VIII concentrate(s) for a minimum of at least 150
             exposure days (as documented by the study site investigator) prior to study entry

          -  Observed decrease of efficacy by subject and/or treating physician after being
             switched from Recombinate rAHF to Advate rAHF-PFM

        Exclusion Criteria:

          -  The participant has a detectable factor VIII inhibitor at screening, with a titer &gt;=
             0.4 Bethesda Unit (BU) (Nijmegen modification of the Bethesda Assay) measured at the
             local and the central laboratory

          -  The participant has a known hypersensitivity to mouse or hamster proteins

          -  The participant is participating in another investigational drug study within 30 days
             prior to screening

          -  The participant is identified by the investigator as being unable or unwilling to
             cooperate with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitt Abbühl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <results_first_submitted>February 13, 2013</results_first_submitted>
  <results_first_submitted_qc>February 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2013</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>9 unique participants enrolled and treated at a single study site in Germany</recruitment_details>
      <pre_assignment_details>Participants required a factor VIII (FVIII) washout period ≥48 hours before receiving any pharmacokinetic (PK) infusions and could not be actively bleeding at the time of the infusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Advate rAHF-PFM Then Recombinate rAHF</title>
          <description>First infusion - Advate Antihemophilic Factor (Recombinant)–Plasma/Albumin Free Method (rAHF-PFM): Infusion of 50 +/- 5 IU/kg bodyweight
Second infusion - Recombinate Antihemophilic Factor (Recombinant) (rAHF): Infusion of 50 +/- 5 IU/kg bodyweight</description>
        </group>
        <group group_id="P2">
          <title>Recombinate rAHF Then Advate rAHF-PFM</title>
          <description>First infusion - Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight
Second infusion - Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First PK Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second PK Infusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Includes groups randomized to receive Advate rAHF-PFM and Recombinate rAHF first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. One-Stage Activated Partial Thromboplastin Time (aPTT) -Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. One-Stage Activated Partial Thromboplastin Time (aPTT) -Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1104" lower_limit="950" upper_limit="1328"/>
                    <measurement group_id="O2" value="1294" lower_limit="1149" upper_limit="1536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.173</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.089</ci_lower_limit>
            <ci_upper_limit>1.262</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1180" lower_limit="999" upper_limit="1497"/>
                    <measurement group_id="O2" value="1358" lower_limit="1146" upper_limit="1547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.139</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>1.243</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="833" lower_limit="697" upper_limit="970"/>
                    <measurement group_id="O2" value="901" lower_limit="629" upper_limit="1070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.060</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.866</ci_lower_limit>
            <ci_upper_limit>1.297</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1505" lower_limit="1215" upper_limit="1741"/>
                    <measurement group_id="O2" value="1664" lower_limit="1340" upper_limit="1911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.071</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.972</ci_lower_limit>
            <ci_upper_limit>1.179</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.
FVIII activity measurement</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.
FVIII activity measurement</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1190" lower_limit="1031" upper_limit="1360"/>
                    <measurement group_id="O2" value="1393" lower_limit="1232" upper_limit="1574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.171</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.099</ci_lower_limit>
            <ci_upper_limit>1.247</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1282" lower_limit="1037" upper_limit="1626"/>
                    <measurement group_id="O2" value="1452" lower_limit="1137" upper_limit="1696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.135</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.092</ci_lower_limit>
            <ci_upper_limit>1.180</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="874" lower_limit="734" upper_limit="1031"/>
                    <measurement group_id="O2" value="926" lower_limit="655" upper_limit="1152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.036</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.857</ci_lower_limit>
            <ci_upper_limit>1.253</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to Infinity. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>All enrolled participants</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1598" lower_limit="1340" upper_limit="1923"/>
                    <measurement group_id="O2" value="1731" lower_limit="1453" upper_limit="2162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.093</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.007</ci_lower_limit>
            <ci_upper_limit>1.186</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (Cl). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (Cl). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>mL/h/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" lower_limit="3.92" upper_limit="4.85"/>
                    <measurement group_id="O2" value="3.68" lower_limit="3.41" upper_limit="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.854</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.798</ci_lower_limit>
            <ci_upper_limit>0.913</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (Cl). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (Cl). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>mL/h/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="3.28" upper_limit="4.88"/>
                    <measurement group_id="O2" value="3.53" lower_limit="3.03" upper_limit="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.881</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.847</ci_lower_limit>
            <ci_upper_limit>0.916</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (Cl). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (Cl). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>mL/h/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" lower_limit="4.40" upper_limit="7.35"/>
                    <measurement group_id="O2" value="5.53" lower_limit="4.28" upper_limit="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.964</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.799</ci_lower_limit>
            <ci_upper_limit>1.164</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (Cl). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (Cl). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Systemic clearance in mL/kg/h will be calculated as the dose in IU/kg divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>mL/h/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="2.63" upper_limit="3.85"/>
                    <measurement group_id="O2" value="2.96" lower_limit="2.35" upper_limit="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.915</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.841</ci_lower_limit>
            <ci_upper_limit>0.995</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (C-max). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (C-max). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
          <population>All enrolled participants</population>
          <units>IU/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="74" upper_limit="112"/>
                    <measurement group_id="O2" value="108" lower_limit="91" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.177</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.104</ci_lower_limit>
            <ci_upper_limit>1.256</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (C-max). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (C-max). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
          <population>All enrolled participants</population>
          <units>IU/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="79" upper_limit="148"/>
                    <measurement group_id="O2" value="119" lower_limit="104" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.152</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.039</ci_lower_limit>
            <ci_upper_limit>1.277</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (C-max). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (C-max). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
          <population>All enrolled participants</population>
          <units>IU/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="66" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="72" upper_limit="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.182</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.029</ci_lower_limit>
            <ci_upper_limit>1.359</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (C-max). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (C-max). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>C-max will be calculated as the maximum concentration following infusion of either Advate or Recombinate.</description>
          <population>All enrolled participants</population>
          <units>IU/dL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="72" upper_limit="121"/>
                    <measurement group_id="O2" value="112" lower_limit="92" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.133</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.010</ci_lower_limit>
            <ci_upper_limit>1.270</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations (9 to 48 hours).</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations (9 to 48 hours).</description>
          <population>All enrolled participants</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="8.3" upper_limit="12.8"/>
                    <measurement group_id="O2" value="10.9" lower_limit="9.1" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.008</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.969</ci_lower_limit>
            <ci_upper_limit>1.050</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
          <population>All enrolled participants</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="8.5" upper_limit="13.5"/>
                    <measurement group_id="O2" value="10.8" lower_limit="8.2" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.964</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.843</ci_lower_limit>
            <ci_upper_limit>1.102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
          <population>All enrolled participants</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="7.5" upper_limit="12.8"/>
                    <measurement group_id="O2" value="9.9" lower_limit="7.6" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.038</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.926</ci_lower_limit>
            <ci_upper_limit>1.163</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Computed from the terminal or disposition rate constant obtained from log-linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
          <population>All enrolled participants</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="9.3" upper_limit="14.2"/>
                    <measurement group_id="O2" value="12.1" lower_limit="8.9" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.015</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.144</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>Increase in factor VIII concentration from pre- to post-infusion.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery. One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>Increase in factor VIII concentration from pre- to post-infusion.</description>
          <population>All enrolled participants</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="1.52" upper_limit="2.10"/>
                    <measurement group_id="O2" value="2.11" lower_limit="1.89" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.178</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.106</ci_lower_limit>
            <ci_upper_limit>1.254</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Computed from the terminal or disposition rate constant obtained from log_e -linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery. Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Computed from the terminal or disposition rate constant obtained from log_e -linear fitting using the least squares deviation to the last five quantifiable concentrations.</description>
          <population>All enrolled participants</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.53" upper_limit="2.70"/>
                    <measurement group_id="O2" value="2.33" lower_limit="2.02" upper_limit="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.152</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.038</ci_lower_limit>
            <ci_upper_limit>1.279</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Increase in factor VIII concentration from pre- to post-infusion</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery. FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Increase in factor VIII concentration from pre- to post-infusion</description>
          <population>All enrolled participants</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="1.24" upper_limit="1.82"/>
                    <measurement group_id="O2" value="1.84" lower_limit="1.49" upper_limit="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.183</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.027</ci_lower_limit>
            <ci_upper_limit>1.362</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Increase in factor VIII concentration from pre- to post-infusion</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery. FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Increase in factor VIII concentration from pre- to post-infusion</description>
          <population>All enrolled participants</population>
          <units>(IU/dL)/(IU/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.44" upper_limit="2.27"/>
                    <measurement group_id="O2" value="2.19" lower_limit="1.74" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.133</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.012</ci_lower_limit>
            <ci_upper_limit>1.270</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="11.0" upper_limit="17.5"/>
                    <measurement group_id="O2" value="14.4" lower_limit="12.1" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.009</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.964</ci_lower_limit>
            <ci_upper_limit>1.056</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="10.9" upper_limit="18.6"/>
                    <measurement group_id="O2" value="14.2" lower_limit="10.3" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.971</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.849</ci_lower_limit>
            <ci_upper_limit>1.112</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="9.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="12.8" lower_limit="10.1" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.020</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.938</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>The MRT in hours will be calculated as total area under the moment curve divided by the total area under the curve.</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="12.4" upper_limit="19.6"/>
                    <measurement group_id="O2" value="16.9" lower_limit="13.2" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.996</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.894</ci_lower_limit>
            <ci_upper_limit>1.111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.25" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.25" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.000</ci_lower_limit>
            <ci_upper_limit>1.000</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.25" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.25" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.303</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.841</ci_lower_limit>
            <ci_upper_limit>2.020</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.25" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.25" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.724</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.304</ci_lower_limit>
            <ci_upper_limit>1.728</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Tmax in hours was defined as the minimum time to reach Maximum plasma concentration (Cmax).</description>
          <population>All enrolled participants</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.25" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.25" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>1.059</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.442</ci_lower_limit>
            <ci_upper_limit>2.539</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
        <description>Computed as weight-adjusted Clearance * Mean Residence Time</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss). One-Stage aPTT-Based Assay Performed at Central Laboratory (Medical University Vienna)</title>
          <description>Computed as weight-adjusted Clearance * Mean Residence Time</description>
          <population>All enrolled participants</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="48.2" upper_limit="75.7"/>
                    <measurement group_id="O2" value="52.9" lower_limit="43.9" upper_limit="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.862</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.807</ci_lower_limit>
            <ci_upper_limit>0.920</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Computed as weight-adjusted Clearance (CL) * Mean Residence Time</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss). Chromogenic Assay Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Computed as weight-adjusted Clearance (CL) * Mean Residence Time</description>
          <population>All enrolled participants</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" lower_limit="45.5" upper_limit="76.6"/>
                    <measurement group_id="O2" value="50.2" lower_limit="45.4" upper_limit="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.855</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.730</ci_lower_limit>
            <ci_upper_limit>1.002</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Computed as weight-adjusted CL * Mean Residence Time</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss). FVIII One-Stage Clotting Assay (Bonn Method) Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Computed as weight-adjusted CL * Mean Residence Time</description>
          <population>All enrolled participants</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" lower_limit="54.6" upper_limit="87.5"/>
                    <measurement group_id="O2" value="70.9" lower_limit="67.5" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.984</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.788</ci_lower_limit>
            <ci_upper_limit>1.228</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
        <description>Computed as weight-adjusted CL * Mean Residence Time</description>
        <time_frame>0-30 minutes before infusion up to 48 hours post-infusion</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Advate rAHF-PFM</title>
            <description>Advate rAHF-PFM: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
          <group group_id="O2">
            <title>Recombinate rAHF</title>
            <description>Recombinate rAHF: Infusion of 50 +/- 5 IU/kg bodyweight</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss). FVIII Clotting Assay. Performed at Local Laboratory (i.e., University of Bonn, the Study Site)</title>
          <description>Computed as weight-adjusted CL * Mean Residence Time</description>
          <population>All enrolled participants</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="40.4" upper_limit="69.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="39.8" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>0.911</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.800</ci_lower_limit>
            <ci_upper_limit>1.039</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>Includes groups randomized to receive Advate rAHF-PFM and Recombinate rAHF first.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter requires a review of results communications (e.g., for confidential information and/or manuscript amendment proposals which do not negatively influence the scientific character of impartiality) ≥30 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigitt Abbühl, MD, Medical Director, Hematology/Hemophilia</name_or_title>
      <organization>Baxter</organization>
      <email>brigitt_abbuehl@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

